NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Viridian Therapeutics, Inc. (VRDN) Stock Analysis

Viridian Therapeutics, Inc. (VRDN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VRDN

$22.92

−$0.04 (−0.17%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VRDN with… →

VRDN Key Statistics

As of Sep 4, 2026
Trading
Open
$22.62
Previous Close
$22.96
Day's Range
22.62–23.03
52-Week Range
13.18–34.29
Volume
759.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.96
Valuation
Market Cap
$2.60B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
36.51
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.39
Financials (FY)
Revenue (FY)
$70.85M+23359.93%
Net Income (FY)
−$342.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
113.29M
1-Year Return
+22.96%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.90M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VRDN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−26.35%
2025+62.34%
2024−11.98%
2023−25.44%
2022+47.75%
2021+20.18%
2020+128.47%
2019−84.16%
2018−70.95%
2017+108.18%
2016 (partial year)−34.51%

As of September 4, 2026.

VRDN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$70.85M−$342.60M−483.6%
2024$302.00K−$269.95M−89387.1%
2023$314.00K−$237.73M−75711.5%
2022$1.77M−$129.87M−7329.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$70.85M—−$363.40M−$342.60M−483.6%
2024$302.00K—−$299.04M−$269.95M−89387.1%
2023$314.00K—−$254.45M−$237.73M−75711.5%
2022$1.77M—−$134.30M−$129.87M−7329.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VRDN Valuation vs Biotechnology Median

Median of 656 stocks
MetricVRDNBiotechnology medianvs median
P/S ratio36.5115.26139% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Viridian Therapeutics, Inc. (VRDN) carries a market capitalisation of $2.60B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 252.

Over the past 52 weeks the price has ranged from $13.18 to $34.29. The most recent close on file for VRDN is $22.92, dated September 4, 2026. That is −$0.04 (−0.17%) against the previous close. The latest close sits 73.9% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $70.85M. That is +23,359.93% against the prior fiscal year, when revenue was $302.00K. The same year closed with a net loss of $342.60M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.39.

Across the 4 fiscal years on file, revenue moves from $1.77M in 2022 to $70.85M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 36.51. On price-to-sales that is 139.18% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +22.96%. Measured over 10 years, that is −15.04% a year compounded. Beta against the wider market is reported at 0.96. Daily returns over the trailing 10 years annualize to a volatility of 133.57%.

Growth & Income

No dividend is on file for VRDN.

Across the complete calendar years on file, 2020 returned +128.47% and 2019 returned −84.16%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −26.35% year to date.

Peer Comparison

Viridian Therapeutics, Inc. (VRDN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Viridian Therapeutics, Inc. VRDN $2.60B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Viridian Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Visit website →